These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103 [TBL] [Abstract][Full Text] [Related]
3. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Mazzone R; Zwergel C; Mai A; Valente S Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Markozashvili D; Ribrag V; Vassetzky YS Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy of cancer with histone deacetylase inhibitors. Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724 [TBL] [Abstract][Full Text] [Related]
6. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970 [TBL] [Abstract][Full Text] [Related]
7. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. Bruyer A; Maes K; Herviou L; Kassambara A; Seckinger A; Cartron G; Rème T; Robert N; Requirand G; Boireau S; Müller-Tidow C; Veyrune JL; Vincent L; Bouhya S; Goldschmidt H; Vanderkerken K; Hose D; Klein B; De Bruyne E; Moreaux J Br J Cancer; 2018 Apr; 118(8):1062-1073. PubMed ID: 29500406 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810 [TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Cotto M; Cabanillas F; Tirado M; García MV; Pacheco E Clin Transl Oncol; 2010 Jun; 12(6):401-9. PubMed ID: 20534395 [TBL] [Abstract][Full Text] [Related]
10. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA. Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic Modifications and Therapy in Multiple Sclerosis. Aslani S; Jafari N; Javan MR; Karami J; Ahmadi M; Jafarnejad M Neuromolecular Med; 2017 Mar; 19(1):11-23. PubMed ID: 27382982 [TBL] [Abstract][Full Text] [Related]
14. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors. Whitmore MA; Li H; Lyu W; Khanam S; Zhang G Front Immunol; 2022; 13():874706. PubMed ID: 35529861 [TBL] [Abstract][Full Text] [Related]
16. Epigenetics of multiple sclerosis: an updated review. Küçükali Cİ; Kürtüncü M; Çoban A; Çebi M; Tüzün E Neuromolecular Med; 2015 Jun; 17(2):83-96. PubMed ID: 24652042 [TBL] [Abstract][Full Text] [Related]
17. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma]. Terui Y Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317 [TBL] [Abstract][Full Text] [Related]